SCHEMBL1890710

SCHEMBL1890710

[CH2][C@H](CNC(=O)OC(C)OC(=O)C(C)(C)C)c1ccc(Cl)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.41
UTS2R Q9UKP6 2/20 0.35
ALDH1A1 P00352 2/20 0.35
KMT2A Q03164 4/20 0.35
MEN1 O00255 3/20 0.35
RAB9A P51151 3/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
ELANE P08246 1/20 0.35
CNR1 P21554 4/20 0.34
CNR2 P34972 2/20 0.34
L3MBTL1 Q9Y468 3/20 0.33
CYP1A2 P05177 2/20 0.33
CYP2C9 P11712 2/20 0.33
HPGD P15428 2/20 0.33
CYP2C19 P33261 2/20 0.33
TDP1 Q9NUW8 2/20 0.33
NPC1 O15118 2/20 0.33
USP2 O75604 1/20 0.33
ABCB11 O95342 1/20 0.33
LMNA P02545 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1886106 1.00 MAPT (0.41) MAPTUTS2RALDH1A1KMT2AMEN1
SCHEMBL1884906 0.85 MAPT (0.42) MAPTUTS2RALDH1A1KMT2AMEN1
SCHEMBL1891741 0.85 MAPT (0.42) MAPTUTS2RALDH1A1KMT2AMEN1
SCHEMBL1884773 0.82 MAPT (0.40) MAPTUTS2RALDH1A1KMT2AMEN1
SCHEMBL1884726 0.82 MAPT (0.40) MAPTUTS2RALDH1A1KMT2AMEN1
SCHEMBL1884816 0.81 MAPT (0.36) MAPTALDH1A1KMT2AMEN1RAB9A
SCHEMBL1884547 0.81 MAPT (0.36) MAPTALDH1A1KMT2AMEN1RAB9A
SCHEMBL27693091 0.79 GAA (0.47) MAPTALDH1A1SMN1; SMN2LMNATSHR
SCHEMBL1886107 0.78 CNR1 (0.38) UTS2RKMT2AMEN1SMN1; SMN2ELANE
SCHEMBL1888802 0.77 MAPT (0.41) MAPTUTS2RALDH1A1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7935686-B2 Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use XENOPORT, INC. (US) 2011-05-03 US disclosed
US-20090124582-A1 Acyloxyalkyl Carbamate Prodrugs, Methods of Synthesis, and Use XENOPORT, INC. (US) 2009-05-14 US disclosed
US-7494985-B2 Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use XENOPORT, INC. (US) 2009-02-24 US disclosed
US-20060111325-A1 Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use XENOPORT, INC. 2006-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060111325-A1 Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use APEH, AASDHPPT, AGPS MAPT 4107/4885UTS2R 1607/4885ALDH1A1 2138/4885
US-20090124582-A1 Acyloxyalkyl Carbamate Prodrugs, Methods of Synthesis, and Use APEH, AASDHPPT, AGPS MAPT 4107/4885UTS2R 1607/4885ALDH1A1 2138/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.